Skip to content
value.today

Trait Biosciences Inc.

Total raised
$20 M
2 rounds on record
Latest round
$12 M
Mar 2021
First round on record
Jul 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Trait Biosciences Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$12 MNo. 2$10 to $50 million

Trait Biosciences Inc.: Raise no. 2, Mar 2021

Investors in this round

4 investors had bought by the notice of Mar 31, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
$1
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$400,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Andrew Templeton Hunter · Executive Officer
  • David William Smalley · Executive Officer
  • Peter J. McDonough · Executive Officer, Director
  • David Templeton Rosenthal · Director
  • Ronan David Levy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • PI Financial Corp. · Vancouver, British Columbia, CanadaSold in no state named, and outside the US
  • Canaccord Genuity Corp. · Vancouver, British Columbia, CanadaSold in no state named, and outside the US

Remarks in the notice

  • On fees: “Canaccord Genuity Corp. and PI Financial Corp. were each issued 1,365,000 common share purchase warrants where each warrant is exercisable into 1 common share at CAD$1.65 per common share for 2 years from issuance”
  • On the amounts: “Total Offering Amount was in Canadian Dollars and was $15,090,312. USD is calculated at exchange rate on closing date.”
  • On the use of proceeds: “Amount above is an estimate of salary per annum.”

Signed by David W. Smalley, Chief Legal Counsel. Source: SEC Form D, newest notice filed Mar 31, 2021. Read the notice at the SEC.

equity, debtSEC
Jul 2019$8 MNo. 1$2 to $10 million

Trait Biosciences Inc.: Raise no. 1, Jul 2019

Investors in this round

4 investors had bought by the notice of Aug 1, 2019: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $15 M offered; $8 M still to sell
Smallest investment taken
$1
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$350,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in British Columbia, Canada

People named in the notice

  • Andrew Templeton Hunter · Executive Officer
  • Aristobulo Thomas Loaiza · Executive Officer
  • David William Smalley · Executive Officer, Director, Promoter
  • Eugene Allan Hodgson · Executive Officer
  • Kimberly Ann Landry · Executive Officer
  • Michael Bruce Harrison · Executive Officer, Director, Promoter
  • Peter J. McDonough · Executive Officer, Director
  • Rebecca Thomas White · Executive Officer
  • Richard Thomas Sayre · Executive Officer, Promoter
  • Richard Todd DeRose · Executive Officer
  • Ronald E. Deutsch · Executive Officer
  • Ronan David Levy · Executive Officer, Director
  • Tawanda Thomas Zidenga · Executive Officer
  • Tichafa Regus Ignatius Munyikwa · Executive Officer
  • Joseph David Del Moral · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Amount above is an estimate of salary per annum.”

Signed by David W. Smalley, Chief Legal Counsel. Source: SEC Form D, newest notice filed Aug 1, 2019. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Trait Biosciences Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2021

That is all the official record says: Trait Biosciences Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Trait Biosciences Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 4 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Trait Biosciences Inc.
NameRoleNamed in
Andrew Templeton HunterExecutive officerMar 2021
David William SmalleyExecutive officerMar 2021
Peter J. McDonoughExecutive officerMar 2021
Aristobulo Thomas LoaizaExecutive officerAug 2019
Eugene Allan HodgsonExecutive officerAug 2019
Kimberly Ann LandryExecutive officerAug 2019
Michael Bruce HarrisonExecutive officerAug 2019
Rebecca Thomas WhiteExecutive officerAug 2019
Richard Thomas SayreExecutive officerAug 2019
Richard Todd DeRoseExecutive officerAug 2019
Ronald E. DeutschExecutive officerAug 2019
Ronan David LevyExecutive officerAug 2019
Tawanda Thomas ZidengaExecutive officerAug 2019
Tichafa Regus Ignatius MunyikwaExecutive officerAug 2019
David Templeton RosenthalDirectorMar 2021
Peter J. McDonoughDirectorMar 2021
Ronan David LevyDirectorMar 2021
David William SmalleyDirectorAug 2019
Joseph David Del MoralDirectorAug 2019
Michael Bruce HarrisonDirectorAug 2019
David William SmalleyPromoterAug 2019
Michael Bruce HarrisonPromoterAug 2019
Richard Thomas SayrePromoterAug 2019